Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neutralizing antibodies for the treatment of COVID-19
Shibo Jiang, Xiujuan Zhang, Yang Yang, et al.
Nature Biomedical Engineering (2020) Vol. 4, Iss. 12, pp. 1134-1139
Open Access | Times Cited: 112

Showing 1-25 of 112 citing articles:

Pathophysiology of COVID-19-associated acute kidney injury
Matthieu Legrand, Samira Bell, Lui G. Forni, et al.
Nature Reviews Nephrology (2021) Vol. 17, Iss. 11, pp. 751-764
Open Access | Times Cited: 417
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Kathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
Cell Reports (2022) Vol. 39, Iss. 7, pp. 110812-110812
Open Access | Times Cited: 396
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
Arvind Gharbharan, Carlijn Jordans, Corine H. GeurtsvanKessel, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 148
The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 136
Factors, enablers and challenges for COVID-19 vaccine development
Jean‐Louis Excler, Mélanie Saville, Lois Privor-Dumm, et al.
BMJ Global Health (2023) Vol. 8, Iss. 6, pp. e011879-e011879
Open Access | Times Cited: 40
Lighting Up Dual-Aptamer-Based DNA Logic-Gated Series Lamp Probes with Specific Membrane Proteins for Sensitive and Accurate Cancer Cell Identification
Xiaoyu Zhou, Chenghao Yu, Xiaoling Wei, et al.
Analytical Chemistry (2025)
Closed Access | Times Cited: 1
Whole Inactivated Virus and Protein-Based COVID-19 Vaccines
Peter J. Hotez, María Elena Bottazzi
Annual Review of Medicine (2021) Vol. 73, Iss. 1, pp. 55-64
Closed Access | Times Cited: 86
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Kathryn Westendorf, Stefanie Žentelis, Lingshu Wang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 81
NeutrobodyPlex—monitoring SARS‐CoV‐2 neutralizing immune responses using nanobodies
Teresa R. Wagner, E. Ostertag, Philipp D. Kaiser, et al.
EMBO Reports (2021) Vol. 22, Iss. 5
Open Access | Times Cited: 58
Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy
Kristian Daniel Ralph Roth, Esther Veronika Wenzel, Maximilian Ruschig, et al.
Frontiers in Cellular and Infection Microbiology (2021) Vol. 11
Open Access | Times Cited: 57
Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications
Endeshaw Chekol Abebe, Tadesse Asmamaw Dejenie
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 35
From concept to delivery: a yeast-expressed recombinant protein-based COVID-19 vaccine technology suitable for global access
Peter J. Hotez, Rakesh Adhikari, Wen‐Hsiang Chen, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 495-500
Open Access | Times Cited: 21
L‐Glycosidase‐Cleavable Natural Glycans Facilitate the Chemical Synthesis of Correctly Folded Disulfide‐Bonded D‐Proteins
Weiwei Shi, Tongyue Wang, Ziyi Yang, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 9
Closed Access | Times Cited: 11
Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses
Yang Yang, Fang Li, Lanying Du
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Kinetics of antibody responses dictate COVID-19 outcome
Carolina Lucas, Jon Klein, Maria E. Sundaram, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 57
Integrative proteomics identifies thousands of distinct, multi-epitope, and high-affinity nanobodies
Yufei Xiang, Zhe Sang, Lirane Bitton, et al.
Cell Systems (2021) Vol. 12, Iss. 3, pp. 220-234.e9
Open Access | Times Cited: 50
Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain–based vaccine candidate, RBD219-N1C1
Jungsoon Lee, Zhuyun Liu, Wen‐Hsiang Chen, et al.
Applied Microbiology and Biotechnology (2021) Vol. 105, Iss. 10, pp. 4153-4165
Open Access | Times Cited: 46
Profiles of current COVID-19 vaccines
Franz X. Heinz, Karin Stiasny
Wiener klinische Wochenschrift (2021) Vol. 133, Iss. 7-8, pp. 271-283
Open Access | Times Cited: 43
Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance
Chiranjib Chakraborty, Manojit Bhattacharya, Ashish Ranjan Sharma
Current Opinion in Pharmacology (2021) Vol. 62, pp. 64-73
Open Access | Times Cited: 43
Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics
Lennox Chitsike, Penelope J. Duerksen-Hughes
Virology Journal (2021) Vol. 18, Iss. 1
Open Access | Times Cited: 41
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 32
Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies
Lanying Du, Yang Yang, Xiujuan Zhang, et al.
Nanoscale (2022) Vol. 14, Iss. 4, pp. 1054-1074
Open Access | Times Cited: 31
A Highly Potent SARS-CoV-2 Blocking Lectin Protein
Recep Erdem Ahan, Alireza Hanifehnezhad, Ebru Şahin Kehribar, et al.
ACS Infectious Diseases (2022) Vol. 8, Iss. 7, pp. 1253-1264
Open Access | Times Cited: 30
A comprehensive review on immunogen and immune-response proteins of SARS-CoV-2 and their applications in prevention, diagnosis, and treatment of COVID-19
Daohong Zhang, Deepak Kukkar, Ki‐Hyun Kim, et al.
International Journal of Biological Macromolecules (2024) Vol. 259, pp. 129284-129284
Closed Access | Times Cited: 6
The Use of Heterologous Antigens for Biopanning Enables the Selection of Broadly Neutralizing Nanobodies Against SARS-CoV-2
V. S. Aripov, Anna V. Zaykovskaya, Ludmila V. Mechetina, et al.
Antibodies (2025) Vol. 14, Iss. 1, pp. 23-23
Open Access
Page 1 - Next Page

Scroll to top